双通道非玻璃体切割眼内激光治疗中重度3A期Coats病的长期结局
该回顾性观察性病例系列纳入2014年3月至2024年5月间接受双通道非玻璃体切割眼内激光治疗(TPNVE)的中重度3A期Coats病患者46例47眼,随访中位67.7个月,全部患眼均获解剖成功,中位治疗次数2.0次,42.5%仅需一次治疗,常见并发症为白内障、玻璃体视网膜纤维化及视网膜下纤维化(各23.4%)。
要点
- TPNVE治疗中重度3A期Coats病全部47眼实现解剖成功,中位治疗2次。
- 42.5%患眼仅需一次TPNVE手术即达解剖成功。
- 渗出性视网膜脱离范围至少4个钟点的患眼中约半数单次手术成功。
核心结论
- TPNVE在消融异常血管和复位视网膜方面对中重度3A期Coats病显示有效。
- 渗出性视网膜脱离范围至少4个钟点的患眼中约半数单次TPNVE手术即获解剖成功。
研究设计与样本
- 回顾性观察性病例系列,纳入2014年3月至2024年5月单一眼科转诊玻璃体视网膜 practice 接受TPNVE的中重度3A期Coats病患者46例47眼。
- 分析解剖成功率、治疗次数及并发症,中位随访67.7个月(范围13.9-135.4个月)。
主要发现
- 47眼中33眼(70.2%)为3A1期,其余为3A2期;渗出性视网膜脱离平均范围6.1个钟点(中位5.0,范围4.0-12.0)。
- 全部47眼均获解剖成功,中位治疗次数2.0次(范围1-6次);TPNVE中位治疗次数1.2次(范围1-2次),传统激光光凝中位0.0次(范围0-4次)。
- 20眼(42.5%)仅需一次治疗;27眼共发生47次复发,其中超过半数(59.5%)发生在最初6个月内。
- 并发症包括白内障11眼(23.4%)、玻璃体视网膜纤维化11眼(23.4%)、视网膜下纤维化11眼(23.4%)、牵拉性视网膜脱离1眼(2.1%)和青光眼1眼(2.1%)。
关键数值与推荐
- 解剖成功定义为全部47眼实现视网膜复位,中位治疗2.0次(范围1-6次)。
- 渗出性视网膜脱离范围至少4个钟点的患眼中约半数单次TPNVE手术获解剖成功。
临床怎么用
- 对于中重度3A期Coats病,TPNVE可作为消融异常血管并复位视网膜的治疗选择。
- 治疗后最初6个月需密切随访,因超过半数复发发生于此期间。
- 需关注白内障、玻璃体视网膜纤维化及视网膜下纤维化等并发症。
局限性
- 回顾性观察性病例系列,单中心、样本量有限(46例47眼)。
- 缺乏对照组,无法与其他治疗方式直接比较。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To report the long-term outcomes of two-port nonvitrectomy endolaser therapy (TPNVE) in moderate-to-severe stage 3A Coats disease. METHODS: In this retrospective observational case series, patients with moderate-to-severe stage 3A Coats disease who were treated with TPNVE in a single tertiary referral vitreoretinal practice between March 2014 and May 2024 were included. The anatomical success rate, number of treatment sessions, and complications were analyzed. RESULTS: Of the 46 patients (47 eyes) included in the study, 33 eyes (70.2%) were stage 3A1, and the rest were stage 3A2. The mean (median, range) extent of exudative retinal detachment was 6.1 (5.0, 4.0-12.0) clock hours. The median (range) follow-up time was 67.7 (13.9-135.4) months. All 47 eyes achieved anatomical success with a median (range) treatment session of 2.0 (1-6) sessions. The median number of TPNVE treatments and conventional laser photocoagulation treatments was 1.2 (range, 1-2) and 0.0 (range, 0-4), respectively. Twenty eyes (42.5%) required only one session. There were 47 instances of recurrence in 27 eyes, of which over half (59.5%) took place in the first 6 months. Complications included cataracts in 11 (23.4%), vitreoretinal fibrosis in 11 (23.4%), subretinal fibrosis in 11 (23.4%), tractional retinal detachment in one (2.1%), and glaucoma in one (2.1%) of the eyes. CONCLUSIONS: TPNVE demonstrated efficacy in ablating abnormal vessels and reattaching the retina for moderate-to-severe stage 3A Coats disease. Approximately half of the eyes with an exudative retinal detachment extent of at least four clock hours achieved anatomical success after a single TPNVE surgery.
引用
- Liu H, Liang T, Zhang W, et al. LONG-TERM OUTCOMES OF TWO-PORT NONVITRECTOMY ENDOLASER THERAPY IN MODERATE-To-SEVERE STAGE 3A COATS DISEASE. Retina. 2026. PMID: 42262544. doi:10.1097/IAE.0000000000004900
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。